XML 49 R32.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment, Geographic and Other Revenue Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Segment Reporting [Abstract] |
Reconciliation of Revenue from Segments to Consolidated |
The following table provides selected income statement information by reportable segment:
|  | Three Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | September 30, 2018 |  |  | October 1, 2017 |  |  | September 30, 2018 |  |  | October 1, 2017 |
Reportable Segments: |  |  |  |  |  |  |  |
IH(b) |  | $ | 8,471 |  |  | $ | 8,118 |  |  | $ | 5,388 |  |  | $ | 5,000 |
EH(b) |  | 4,826 |  |  | 5,050 |  |  | 2,527 |  |  | 2,801 |
Total reportable segments |  | 13,298 |  |  | 13,168 |  |  | 7,915 |  |  | 7,801 |
Other business activities(c), (d) |  | — |  |  | — |  |  | (736 | ) |  | (759 | )
Reconciling Items: |  |  |  |  |  |  |  |  |  |
Corporate(b), (d) |  | — |  |  | — |  |  | (1,337 | ) |  | (1,363 | )
Purchase accounting adjustments(d) |  | — |  |  | — |  |  | (1,309 | ) |  | (1,154 | )
Acquisition-related costs(d) |  | — |  |  | — |  |  | (112 | ) |  | (155 | )
Certain significant items(e) |  | — |  |  | — |  |  | 213 |  |  | (449 | )
Other unallocated(b), (d) |  | — |  |  | — |  |  | (457 | ) |  | (335 | )
|  | $ | 13,298 |  |  | $ | 13,168 |  |  | $ | 4,177 |  |  | $ | 3,585 |
|  | Nine Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | September 30, 2018 |  |  | October 1, 2017 |  |  | September 30, 2018 |  |  | October 1, 2017 |
Reportable Segments: |  |  |  |  |  |  |  |
IH(b) |  | $ | 24,573 |  |  | $ | 23,204 |  |  | $ | 15,419 |  |  | $ | 14,534 |
EH(b) |  | 15,097 |  |  | 15,639 |  |  | 8,133 |  |  | 8,672 |
Total reportable segments |  | 39,670 |  |  | 38,843 |  |  | 23,552 |  |  | 23,206 |
Other business activities(c), (d) |  | — |  |  | — |  |  | (2,130 | ) |  | (2,205 | )
Reconciling Items: |  |  |  |  |  |  |  |
Corporate(b), (d) |  | — |  |  | — |  |  | (3,633 | ) |  | (3,908 | )
Purchase accounting adjustments(d) |  | — |  |  | — |  |  | (3,665 | ) |  | (3,527 | )
Acquisition-related costs(d) |  | — |  |  | — |  |  | (221 | ) |  | (347 | )
Certain significant items(e) |  | — |  |  | — |  |  | (8 | ) |  | (797 | )
Other unallocated(b), (d) |  | — |  |  | — |  |  | (1,064 | ) |  | (1,070 | )
|  | $ | 39,670 |  |  | $ | 38,843 |  |  | $ | 12,831 |  |  | $ | 11,351 |
(a) | Income from continuing operations before provision for taxes on income. IH’s earnings include d ividend income of $91 million and $54 million in the third quarter of 2018 and 2017, respectively, and $226 million and $211 million in the first nine months of 2018 and 2017, respectively, from our investment in ViiV. For additional information, see Note 4.
(b) | In connection with the StratCO reporting change, in the third quarter of 2017, we reclassified approximately $125 million of costs from IH, approximately $36 million of costs from EH and approximately $19 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. In the first nine months of 2017, we reclassified approximately $344 million of costs from IH, approximately $114 million of costs from EH and approximately $40 million of costs from Corporate to Other unallocated costs to conform to the current period presentation.
(c) | Other business activities includes the costs managed by our WRD and GPD organizations.
(d) | For a description, see the “Other Costs and Business Activities” section above.
(e) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in the third quarter of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction ini tiatives that are not associated with an acquisition of $35 million, (ii) net charges for certain legal matters of $37 million, (iii) income of $2 million, representing an adjustment t o amounts previously recorded to write down the HIS net assets to fair value less costs to sell and (iv) other income of $282 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2017, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $55 million, (ii) charges for certain legal matters of $183 million, (iii) income of $12 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million, (v) charges for business and legal entity alignment of $16 million and (vi) other charges of $81 million, which includes, among other things, $55 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico and are included in Cost of sales. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $127 million, (ii) net credits for certain legal matters of $70 million, (iii) income of $1 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $31 million, (v) charges for business and legal entity alignment of $4 million and (vi) other income of $84 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, information and administrative expenses, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA on us, and a $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic chimeric antigen receptor T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2017, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $133 million, (ii) charges for certain legal matters of $191 million, (iii) charges of $52 million, representing adjustments to amounts previously recorded to write-down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million, (v) charges for business and legal entity alignment of $54 million and (v) other charges of $239 million, which include, among other things, $55 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico and are included in Cost of sales, and a net loss of $30 million related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the then remaining 60% ownership interest, which is included in Other (income)/deductions––net. For additional information, see Note 2B, Note 3 and Note 4.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
The following table provides selected income statement information by reportable segment:
|  | Three Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | September 30, 2018 |  |  | October 1, 2017 |  |  | September 30, 2018 |  |  | October 1, 2017 |
Reportable Segments: |  |  |  |  |  |  |  |
IH(b) |  | $ | 8,471 |  |  | $ | 8,118 |  |  | $ | 5,388 |  |  | $ | 5,000 |
EH(b) |  | 4,826 |  |  | 5,050 |  |  | 2,527 |  |  | 2,801 |
Total reportable segments |  | 13,298 |  |  | 13,168 |  |  | 7,915 |  |  | 7,801 |
Other business activities(c), (d) |  | — |  |  | — |  |  | (736 | ) |  | (759 | )
Reconciling Items: |  |  |  |  |  |  |  |  |  |
Corporate(b), (d) |  | — |  |  | — |  |  | (1,337 | ) |  | (1,363 | )
Purchase accounting adjustments(d) |  | — |  |  | — |  |  | (1,309 | ) |  | (1,154 | )
Acquisition-related costs(d) |  | — |  |  | — |  |  | (112 | ) |  | (155 | )
Certain significant items(e) |  | — |  |  | — |  |  | 213 |  |  | (449 | )
Other unallocated(b), (d) |  | — |  |  | — |  |  | (457 | ) |  | (335 | )
|  | $ | 13,298 |  |  | $ | 13,168 |  |  | $ | 4,177 |  |  | $ | 3,585 |
|  | Nine Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | September 30, 2018 |  |  | October 1, 2017 |  |  | September 30, 2018 |  |  | October 1, 2017 |
Reportable Segments: |  |  |  |  |  |  |  |
IH(b) |  | $ | 24,573 |  |  | $ | 23,204 |  |  | $ | 15,419 |  |  | $ | 14,534 |
EH(b) |  | 15,097 |  |  | 15,639 |  |  | 8,133 |  |  | 8,672 |
Total reportable segments |  | 39,670 |  |  | 38,843 |  |  | 23,552 |  |  | 23,206 |
Other business activities(c), (d) |  | — |  |  | — |  |  | (2,130 | ) |  | (2,205 | )
Reconciling Items: |  |  |  |  |  |  |  |
Corporate(b), (d) |  | — |  |  | — |  |  | (3,633 | ) |  | (3,908 | )
Purchase accounting adjustments(d) |  | — |  |  | — |  |  | (3,665 | ) |  | (3,527 | )
Acquisition-related costs(d) |  | — |  |  | — |  |  | (221 | ) |  | (347 | )
Certain significant items(e) |  | — |  |  | — |  |  | (8 | ) |  | (797 | )
Other unallocated(b), (d) |  | — |  |  | — |  |  | (1,064 | ) |  | (1,070 | )
|  | $ | 39,670 |  |  | $ | 38,843 |  |  | $ | 12,831 |  |  | $ | 11,351 |
(a) | Income from continuing operations before provision for taxes on income. IH’s earnings include d ividend income of $91 million and $54 million in the third quarter of 2018 and 2017, respectively, and $226 million and $211 million in the first nine months of 2018 and 2017, respectively, from our investment in ViiV. For additional information, see Note 4.
(b) | In connection with the StratCO reporting change, in the third quarter of 2017, we reclassified approximately $125 million of costs from IH, approximately $36 million of costs from EH and approximately $19 million of costs from Corporate to Other unallocated costs to conform to the current period presentation. In the first nine months of 2017, we reclassified approximately $344 million of costs from IH, approximately $114 million of costs from EH and approximately $40 million of costs from Corporate to Other unallocated costs to conform to the current period presentation.
(c) | Other business activities includes the costs managed by our WRD and GPD organizations.
(d) | For a description, see the “Other Costs and Business Activities” section above.
(e) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in the third quarter of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction ini tiatives that are not associated with an acquisition of $35 million, (ii) net charges for certain legal matters of $37 million, (iii) income of $2 million, representing an adjustment t o amounts previously recorded to write down the HIS net assets to fair value less costs to sell and (iv) other income of $282 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2017, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $55 million, (ii) charges for certain legal matters of $183 million, (iii) income of $12 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million, (v) charges for business and legal entity alignment of $16 million and (vi) other charges of $81 million, which includes, among other things, $55 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico and are included in Cost of sales. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2018, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $127 million, (ii) net credits for certain legal matters of $70 million, (iii) income of $1 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $31 million, (v) charges for business and legal entity alignment of $4 million and (vi) other income of $84 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, information and administrative expenses, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA on us, and a $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic chimeric antigen receptor T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the first nine months of 2017, certain significant items includes: (i) restructuring credits and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $133 million, (ii) charges for certain legal matters of $191 million, (iii) charges of $52 million, representing adjustments to amounts previously recorded to write-down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million, (v) charges for business and legal entity alignment of $54 million and (v) other charges of $239 million, which include, among other things, $55 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico and are included in Cost of sales, and a net loss of $30 million related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the then remaining 60% ownership interest, which is included in Other (income)/deductions––net. For additional information, see Note 2B, Note 3 and Note 4.
Schedule of Revenues by Geographic Region |
The following table provides revenues by geographic area:
|  | Three Months Ended |  | Nine Months Ended
(MILLIONS OF DOLLARS) |  | September 30, 2018 |  |  | October 1, 2017 |  |  | % Change |  |  | September 30, 2018 |  |  | October 1, 2017 |  |  | % Change |
U.S. |  | $ | 6,361 |  |  | $ | 6,534 |  |  | (3 | ) |  | $ | 18,861 |  |  | $ | 19,516 |  |  | (3 | )
Developed Europe(a) |  | 2,231 |  |  | 2,163 |  |  | 3 |  |  | 6,657 |  |  | 6,309 |  |  | 6 |
Developed Rest of World(b) |  | 1,640 |  |  | 1,632 |  |  | 1 |  |  | 4,795 |  |  | 4,797 |  |  | — |
Emerging Markets(c) |  | 3,066 |  |  | 2,839 |  |  | 8 |  |  | 9,358 |  |  | 8,222 |  |  | 14 |
Revenues |  | $ | 13,298 |  |  | $ | 13,168 |  |  | 1 |  |  | $ | 39,670 |  |  | $ | 38,843 |  |  | 2 |
(a) | Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.8 billion and $1.7 billion in the third quarter of 2018 and 2017, respectively, and $5.3 billion and $5.0 billion in the first nine months of 2018 and 2017, respectively.
(b) | Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.
(c) | Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Schedule of Significant Product Revenues |
The following table provides detailed revenue information:
(MILLIONS OF DOLLARS) |  |  |  | Three Months Ended |  | Nine Months Ended |
PRODUCT |  | PRIMARY INDICATIONS OR CLASS |  | September 30, 2018 |  |  | October 1, 2017 |  |  | September 30, 2018 |  |  | October 1, 2017 |
TOTAL REVENUES |  |  |  | $ | 13,298 |  |  | $ | 13,168 |  |  | $ | 39,670 |  |  | $ | 38,843 |
PFIZER INNOVATIVE HEALTH (IH)(a) |  | $ | 8,471 |  |  | $ | 8,118 |  |  | $ | 24,573 |  |  | $ | 23,204 |
Internal Medicine |  |  |  | $ | 2,463 |  |  | $ | 2,455 |  |  | $ | 7,339 |  |  | $ | 7,245 |
Lyrica IH(b) |  | Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury |  | 1,132 |  |  | 1,150 |  |  | 3,398 |  |  | 3,382 |
Eliquis alliance revenues and direct sales |  | Atrial fibrillation, deep vein thrombosis, pulmonary embolism |  | 870 |  |  | 644 |  |  | 2,524 |  |  | 1,813 |
Chantix/Champix |  | An aid to smoking cessation treatment in adults 18 years of age or older |  | 261 |  |  | 240 |  |  | 789 |  |  | 727 |
BMP2 |  | Development of bone and cartilage |  | 54 |  |  | 79 |  |  | 206 |  |  | 198 |
Toviaz |  | Overactive bladder |  | 67 |  |  | 62 |  |  | 197 |  |  | 187 |
Viagra IH(c) |  | Erectile dysfunction |  | — |  |  | 206 |  |  | — |  |  | 711 |
All other Internal Medicine |  | Various |  | 79 |  |  | 75 |  |  | 224 |  |  | 228 |
Vaccines |  |  |  | $ | 1,845 |  |  | $ | 1,649 |  |  | $ | 4,708 |  |  | $ | 4,385 |
Prevnar 13/Prevenar 13 |  | Vaccines for prevention of pneumococcal disease |  | 1,660 |  |  | 1,522 |  |  | 4,290 |  |  | 4,069 |
FSME/IMMUN-TicoVac |  | Tick-borne encephalitis vaccine |  | 57 |  |  | 43 |  |  | 162 |  |  | 119 |
Trumenba |  | Meningococcal Group B vaccine |  | 61 |  |  | 42 |  |  | 95 |  |  | 79 |
All other Vaccines |  | Various |  | 67 |  |  | 43 |  |  | 160 |  |  | 117 |
Oncology |  |  |  | $ | 1,775 |  |  | $ | 1,616 |  |  | $ | 5,294 |  |  | $ | 4,551 |
Ibrance |  | Advanced breast cancer |  | 1,025 |  |  | 878 |  |  | 2,985 |  |  | 2,410 |
Sutent |  | Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor |  | 248 |  |  | 276 |  |  | 785 |  |  | 805 |
Xtandi alliance revenues |  | Castration-resistant prostate cancer |  | 180 |  |  | 150 |  |  | 510 |  |  | 422 |
Xalkori |  | ALK-positive and ROS1-positive advanced NSCLC |  | 127 |  |  | 146 |  |  | 417 |  |  | 442 |
Inlyta |  | Advanced RCC |  | 71 |  |  | 84 |  |  | 226 |  |  | 256 |
Bosulif |  | Philadelphia chromosome–positive chronic myelogenous leukemia |  | 69 |  |  | 57 |  |  | 206 |  |  | 163 |
All other Oncology |  | Various |  | 55 |  |  | 26 |  |  | 164 |  |  | 54 |
Inflammation & Immunology (I&I) |  |  |  | $ | 1,018 |  |  | $ | 1,000 |  |  | $ | 2,951 |  |  | $ | 2,863 |
Enbrel (Outside the U.S. and Canada) |  | Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis |  | 531 |  |  | 613 |  |  | 1,589 |  |  | 1,818 |
Xeljanz |  | Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis |  | 432 |  |  | 348 |  |  | 1,221 |  |  | 935 |
Eucrisa |  | Mild-to-moderate atopic dermatitis (eczema) |  | 40 |  |  | 15 |  |  | 104 |  |  | 33 |
All other I&I |  | Various |  | 15 |  |  | 23 |  |  | 37 |  |  | 78 |
Rare Disease |  |  |  | $ | 531 |  |  | $ | 569 |  |  | $ | 1,651 |  |  | $ | 1,637 |
BeneFIX |  | Hemophilia |  | 132 |  |  | 151 |  |  | 420 |  |  | 453 |
Genotropin |  | Replacement of human growth hormone |  | 143 |  |  | 136 |  |  | 416 |  |  | 375 |
Refacto AF/Xyntha |  | Hemophilia |  | 117 |  |  | 140 |  |  | 388 |  |  | 409 |
Somavert |  | Acromegaly |  | 64 |  |  | 65 |  |  | 195 |  |  | 182 |
All other Rare Disease |  | Various |  | 74 |  |  | 77 |  |  | 232 |  |  | 218 |
Consumer Healthcare |  |  |  | $ | 839 |  |  | $ | 829 |  |  | $ | 2,631 |  |  | $ | 2,522 |
PFIZER ESSENTIAL HEALTH (EH)(d) |  |  |  | $ | 4,826 |  |  | $ | 5,050 |  |  | $ | 15,097 |  |  | $ | 15,639 |
Legacy Established Products (LEP)(e) |  |  |  | $ | 2,533 |  |  | $ | 2,681 |  |  | $ | 7,865 |  |  | $ | 7,995 |
Lipitor |  | Reduction of LDL cholesterol |  | 507 |  |  | 491 |  |  | 1,539 |  |  | 1,341 |
Norvasc |  | Hypertension |  | 247 |  |  | 226 |  |  | 773 |  |  | 684 |
Premarin family |  | Symptoms of menopause |  | 204 |  |  | 238 |  |  | 605 |  |  | 711 |
Xalatan/Xalacom |  | Glaucoma and ocular hypertension |  | 76 |  |  | 83 |  |  | 233 |  |  | 241 |
Effexor |  | Depression and certain anxiety disorders |  | 78 |  |  | 76 |  |  | 228 |  |  | 215 |
Zoloft |  | Depression and certain anxiety disorders |  | 72 |  |  | 78 |  |  | 223 |  |  | 215 |
Zithromax |  | Bacterial infections |  | 54 |  |  | 61 |  |  | 216 |  |  | 202 |
EpiPen |  | Epinephrine injection used in treatment of life-threatening allergic reactions |  | 68 |  |  | 82 |  |  | 215 |  |  | 253 |
Xanax |  | Anxiety disorders |  | 52 |  |  | 58 |  |  | 163 |  |  | 164 |
Sildenafil Citrate |  | Erectile dysfunction |  | 1 |  |  | — |  |  | 72 |  |  | — |
All other LEP |  | Various |  | 1,176 |  |  | 1,288 |  |  | 3,599 |  |  | 3,969 |
(MILLIONS OF DOLLARS) |  |  |  | Three Months Ended |  | Nine Months Ended |
PRODUCT |  | PRIMARY INDICATIONS OR CLASS |  | September 30, 2018 |  |  | October 1, 2017 |  |  | September 30, 2018 |  |  | October 1, 2017 |
Sterile Injectable Pharmaceuticals (SIP)(f) |  | $ | 1,239 |  |  | $ | 1,273 |  |  | $ | 3,928 |  |  | $ | 4,270 |
Sulperazon |  | Treatment of infections |  | 145 |  |  | 114 |  |  | 464 |  |  | 345 |
Medrol |  | Steroid anti-inflammatory |  | 95 |  |  | 109 |  |  | 318 |  |  | 352 |
Fragmin |  | Slows blood clotting |  | 76 |  |  | 79 |  |  | 221 |  |  | 221 |
Tygacil |  | Tetracycline class antibiotic |  | 60 |  |  | 60 |  |  | 186 |  |  | 192 |
Zosyn/Tazocin |  | Antibiotic |  | 55 |  |  | 47 |  |  | 175 |  |  | 124 |
Precedex |  | Sedation agent in surgery or intensive care |  | 47 |  |  | 51 |  |  | 166 |  |  | 182 |
All other SIP |  | Various |  | 761 |  |  | 814 |  |  | 2,399 |  |  | 2,852 |
Peri-LOE Products(g) |  |  |  | $ | 698 |  |  | $ | 794 |  |  | $ | 2,208 |  |  | $ | 2,398 |
Viagra EH(c) |  | Erectile dysfunction |  | 137 |  |  | 102 |  |  | 509 |  |  | 285 |
Celebrex |  | Arthritis pain and inflammation, acute pain |  | 188 |  |  | 212 |  |  | 494 |  |  | 564 |
Vfend |  | Fungal infections |  | 87 |  |  | 97 |  |  | 294 |  |  | 305 |
Lyrica EH(b) |  | Epilepsy, neuropathic pain and generalized anxiety disorder |  | 81 |  |  | 134 |  |  | 251 |  |  | 428 |
Zyvox |  | Bacterial infections |  | 50 |  |  | 68 |  |  | 184 |  |  | 220 |
Revatio |  | Pulmonary arterial hypertension |  | 53 |  |  | 58 |  |  | 163 |  |  | 189 |
Pristiq |  | Depression |  | 52 |  |  | 69 |  |  | 156 |  |  | 230 |
All other Peri-LOE Products |  | Various |  | 49 |  |  | 55 |  |  | 157 |  |  | 176 |
Biosimilars(h) |  | Various |  | $ | 197 |  |  | $ | 141 |  |  | $ | 558 |  |  | $ | 367 |
Inflectra/Remsima |  | Inflammatory diseases |  | 166 |  |  | 112 |  |  | 469 |  |  | 284 |
All other Biosimilars |  | Various |  | 31 |  |  | 28 |  |  | 89 |  |  | 82 |
Pfizer CentreOne(i) |  |  |  | $ | 159 |  |  | $ | 161 |  |  | $ | 539 |  |  | $ | 514 |
Hospira Infusion Systems (HIS)(j) |  | Various |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 97 |
Total Lyrica(b) |  | Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury |  | $ | 1,213 |  |  | $ | 1,285 |  |  | $ | 3,649 |  |  | $ | 3,810 |
Total Viagra(c) |  | Erectile dysfunction |  | $ | 137 |  |  | $ | 308 |  |  | $ | 509 |  |  | $ | 996 |
Total Alliance revenues |  | Various |  | $ | 977 |  |  | $ | 741 |  |  | $ | 2,820 |  |  | $ | 2,112 |
(a) | The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare.
(b) | Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
(c) | Viagra lost exclusivity in the U.S. in December 2017. Beginning in 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, are reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, beginning in 2018, total Viagra revenues are reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
(d) | The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017).
(e) | Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
(f) | Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
(g) | Peri-LOE Products includes products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and beginning in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017, see note (c) above).
(h) | Biosimilars includes Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and in the U.S. and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.
(i) | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
(j) | HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration